Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Q1 Revenues Inch up 1 Percent

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that its revenues in the first quarter inched up a little more than 1 percent year over year.

For the three months ended March 31, LabCorp's revenues reached $1.44 billion, up from $1.42 billion a year ago, and just short of the $1.45 billion consensus Wall Street estimate. Testing volume, measured by requisitions was up 1 percent, while revenue per requisition increased .2 percent, LabCorp said, adding that inclement weather reduced volume growth by .5 percent.

LabCorp's profit in the quarter narrowed to $147.6 million, or $1.56 per share, compared to $162.0 million, or $1.63 per share, a year ago. On an adjusted basis, EPS was $1.74, missing the average Wall Street estimate of $1.77.

The firm's SG&A expenses rose 4 percent to $283.2 million from $271.2 million. Also, the company took restructuring and other special charges of $7.5 million during the quarter, compared to a credit of $3.6 million a year ago.

LabCorp ended the quarter with $185.8 million in cash and short-term investments.

It reaffirmed its full-year 2013 guidance of revenue growth in the 2 percent to 3 percent range. Adjusted EPS, excluding amortization, is expected in the $6.85 to $7.15 range, which includes a negative impact of $.35 from reduced Medicare payments.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.